RxDoctor Payments Data

William Ware, MD

Internal Medicine · Aston, PANPI 1497716849

Payments from drug & device makers

$25,703in general payments, 2019–2025

Across 1,263 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • GSK$2K
  • Lilly USA, LLC$2K
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$2,4009%
  • Travel & lodging$440%
  • Food & beverage$23,15390%
  • Education$1070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer113$4,083
Novo Nordisk143$2,560
AstraZeneca109$2,251
AbbVie(2 entities)127$2,089
GSK97$1,763
Lilly USA, LLC88$1,516
Amgen(2 entities)66$1,240
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC64$982
Sanofi-aventis U.S. LLC51$974
Harmony Biosciences LLC29$876
Boehringer Ingelheim40$824
Astellas Pharma US Inc32$624
Amarin Pharma, Inc.28$539
Teva Pharmaceuticals USA, Inc.31$538
Novartis30$520
Otsuka America Pharmaceutical, Inc.22$416
Exact Sciences17$372
Bayer16$367
Axsome Therapeutics, Inc.12$327
Merck19$302
Braeburn Inc.6$225
Collegium Pharmaceutical, Inc.8$162
Esperion Therapeutics, Inc.9$162
Biohaven Pharmaceutical Holding Company Ltd.7$141
Paratek Pharmaceuticals, Inc.7$136
Phathom Pharmaceuticals, Inc.9$132
Sumitomo Pharma America, Inc.6$119
Seqirus USA Inc5$111
Kowa Pharmaceuticals America, Inc.7$111
Indivior Inc.6$109
Biohaven Pharmaceuticals, Inc.5$101
Alkermes, Inc.3$77
Idorsia Pharmaceuticals US Inc4$75
Takeda Pharmaceuticals U.S.A., Inc.3$65
Almatica Pharma LLC3$63
Johnson & Johnson4$62
Ardelyx, Inc.3$59
Eisai Inc.3$59
Dexcom, Inc.2$56
Scilex Pharmaceuticals Inc.3$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$52
Philips North America LLC3$51
Shield Therapeutics Inc1$44
E.r. Squibb & Sons, L.L.C.3$41
Lundbeck LLC1$25
Adlon Therapeutics L.p.1$23
Aytu Biopharma, Inc.1$23
Abbott1$22
Inspire Medical Systems, Inc.1$21
Evoke Pharma, Inc.1$20
Xeris Pharmaceuticals, Inc.1$17
Radius Health, Inc.1$17
Gilead1$16
Nestle Healthcare Nutrition Inc.1$15
Shire North American Group Inc1$14
Regeneron Healthcare Solutions, Inc.1$14
Hikma Pharmaceuticals USA1$13
Eyevance Pharmaceuticals LLC1$13
Theracosbio, LLC1$12
Sanofi Pasteur Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,703 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$697,102
Medicare patients
1,261
Services billed
6,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$123,919
MounjaroTirzepatide67$80,004
FarxigaDapagliflozin Propanediol71$75,922
OzempicSemaglutide52$73,933
JardianceEmpagliflozin45$47,893
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$45,631
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$43,611
OxycontinOxycodone Hcl21$28,629
TrulicityDulaglutide13$24,532
Bydureon BciseExenatide Microspheres11$18,527
WegovySemaglutide13$16,855
ShingrixVaricella-Zoster Ge/As01b/Pf63$13,872
ArexvyRsvpref3 Antigen/As01e/Pf33$10,099
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$9,804
MyrbetriqMirabegron14$9,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$2,251$135,603159 claims
PfizerEliquis, Dilantin$4,083$127,578147 claims
Lilly USA, LLCMounjaro, Trulicity$1,516$104,53780 claims
Novo NordiskOzempic, Wegovy$2,560$90,78865 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$1,763$69,603164 claims
Boehringer IngelheimJardiance$824$47,89345 claims
AbbVieLinzess, Synthroid$2,089$11,05569 claims
Astellas Pharma US IncMyrbetriq$624$9,56814 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$13$6,49254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Aston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →